September 2009 Medtech Financings (to date)


  • Endosense, Inc., has raised $36 million in a Series B financing (catheter ablation of cardiac arrhythmias)
  • Athena Feminine Technologies has raised $2 million in a Series A financing (pelvic floor electrical stimulation for treatment of urinary incontinence) 
  • ValenTx, Inc., has raised $22 million in Series B financing (minimally invasive treatment of obesity)
  • LifeWave Hi-Tech Medical Devices Ltd has raised $1.5 million in a secondary offering (electrical stimulation device for chronic wound treatment)
  • Uptake Medical, Inc., has raised $3.4 million of a planned $13.4 million financing according to a regulatory filing (broncoscopic catheters for treatment of emphysema and chronic obstructive pulmonary disease)
  • Nuveta, Inc., has raised $800K in a Series A financing (in vitro fertilization technologies)
  • Virtual Ports, Ltd., has raised $2.6 million in early stage financing (developing surgical endoscopy technology)
  • Pervasis Therapeutics, Inc., has raised $17 million in a Series C financing (Vascugel, a product derived from tissue-engineered allogeneic endothelium for enhancing blood vessel repair) 
  • Calypso Medical Technologies, Inc., has raised $50 million in venture capital financing (tumor localization technology for use during external beam radiation therapy)

With both July and August medtech financings in excess of $400 million, it was perhaps wishful thinking on my part that September stay on pace, but being that investment in September has a tendency to be depressed (or so I have heard), the month-to-date financing for September of just over $100 million has the month well off the last two months’ torrid pace.

Posted via web from medmarket’s posterous

Leave a Reply